<DOC>
	<DOCNO>NCT00633529</DOCNO>
	<brief_summary>To evaluate safety propose Phase II dosage investigational drug IMO 2055 combine erlotinib bevacizumab patient previously treat advanced NSCLC .</brief_summary>
	<brief_title>Safety Adding IMO-2055 Erlotinib + Bevacizumab 2nd Line Treatment Patients With NSCLC</brief_title>
	<detailed_description>Phase 1b study escalate dos weekly subcutaneous IMO-2055 combine fixed standard dose regimens oral erlotinib ( daily ) IV bevacizumab ( every 3 week ) patient previously treat advanced NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion : Patients must satisfy follow inclusion criterion order eligible study : 1 . Signed write informed consent 2 . AJCC stage 3 4 histologically proven NSCLC amenable curative therapy erlotinib bevacizumab therapy would appropriate 3 . Radiological assessment within 21 day prior inclusion , measurable disease present 4 . Age ≥ 18 year 5 . ECOG performance status 0 1 6 . Patient receive least one standard platinumcontaining chemotherapy regimen appropriate his/her lung cancer , opinion investigator , prior enrollment . Exclusion : Patients follow excluded participation study : Disease 1 . Squamous cell carcinoma , except patient intrathoracic disease small peripheral lesion . 2 . Known central nervous system ( CNS ) metastases ( Note : patient brain metastasis control ≥ 4 month without use steroid eligible ) . Prior Treatments 3 . Less 4 week registration last receipt chemotherapy , biotherapy , radiotherapy major surgery 4 . Concurrent plan hormonal agent replacement therapy , oral contraceptive , anticancer therapy , e.g . Megace . ( A prior history therapy exclusionary . ) 5 . Administration investigational agent ( therapeutic diagnostic ) , include investigational compound treatment NSCLC , within 4 week prior first study dose Other Concomitant Medications 6 . High dose oral intravenous corticosteroid . ( Note : topical , inhaled intraarticular corticosteroid allow . Prophylactic antihistamine allow administration bevacizumab 7 . Use medication strong inhibitor inducer cytochrome P450 isoform CYP3A4 ( see Appendix 5 ) 8 . Therapeutic dose warfarin &gt; 1 mg/day 9 . Chronic daily use aspirin ( &gt; 325 mg/day ) fulldose NSAIDs antiplatelet activity 10 . Inability take oral medication requirement IV alimentation total parenteral nutrition lipid , prior surgical procedure affect absorption Laboratory 11 . The following laboratory result , within 10 day first study drug administration : Hemoglobin ≤ 9.0 g/dL Absolute neutrophil count ≤ 1.5 x 109/L Platelet count ≤ 100 x 109/L International Normalized Ratio ( INR ) &gt; 1.3 ( subject warfarin [ &lt; 1 mg per day ] ) 28 day prior enrollment . aPTT &gt; Upper Limit Normal ( ULN ) 28 day prior enrollment . Serum creatinine ≥ 1.5 x ULN creatinine clearance ( CockcroftGault formula ) &lt; 60 mL/min Serum bilirubin ≥ 1.5 x ULN Proteinuria : UPC ≥ 1.0 ≥ 2+ proteinuria urine dipstick , unless 24hour urine demonstrates &lt; 1.0 g/24 hour ALT AST ≥ 2.5 x ULN ( ≥ 5 x ULN liver metastasis ) Alkaline phosphatase ≥ 2.5 x ULN Albumin ≤ 2.5 g/L Women child bear potential : positive pregnancy test ( serum ) . Other Conditions Procedures 12 . Any clinically significant adverse event prior chemotherapy , surgery radiotherapy yet resolve CTCAE v3.0 grade ≤ 1 13 . Known hypersensitivity oligodeoxynucleotide ( ODN ) , EGFRinhibitor bevacizumab 14 . Serious , nonhealing wound , ulcer bone fracture 15 . Patients history current neoplasm entry diagnosis , except curatively treat nonmelanoma skin cancer carcinoma situ cervix except cancer treated cure diseasefree survival great 5 year . 16 . Pregnant breastfeed woman 17 . Men woman childbearing potential refuse unable use acceptable mean contraception 18 . History clinically significant hemoptysis within 3 month prior registration unless definitively treat surgery radiation 19 . Any medical condition would impose excessive risk patient , uncontrolled hypertension ( systolic &gt; 150 mmHg diastolic &gt; 100 mmHg per JNC 7 guideline , congestive heart failure NYHA Class 24 , uncontrolled unstable angina , myocardial infarction within previous 6 month , ventricular arrhythmia , infection require parental oral antiinfective treatment , alter mental status psychiatric condition would interfere understand informed consent , uncontrolled seizure , chronic hepatitis cirrhosis , know human immunodeficiency virus ( HIV ) infection , know hepatitis B surface antigen ( HBsAg ) positive uncontrolled diabetes . ( Note : testing HIV infection HBsAg part screen assessment performed central laboratory ) . 20 . Preexisting autoimmune antibodymediated disease , include , limited , follow : systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome autoimmune thrombocytopenia 21 . Evidence bleed diathesis coagulopathy serious acute internal bleeding within 6 month prior registration 22 . CNS bleeding ; history clinical evidence CNS stroke ( hemorrhagic thrombotic ) within last 6 month 23 . History allogeneic organ transplant 24 . Brain biopsy within 12 week first study dose 25 . Minor surgical procedure , central venous catheter placement , fine needle aspiration core biopsy within 7 day prior first study dose 26 . Anticipation need major surgical procedure course study Other 27 . Unwilling unable comply protocol duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Phase 1b</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Advanced Metastatic Disease</keyword>
	<keyword>Prior chemotherapy</keyword>
</DOC>